Media stories about Jounce Therapeutics (NASDAQ:JNCE) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Jounce Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.813500693129 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Why Jounce Shares Are Crumbling Ahead of ASCO (247wallst.com)
- Jounce Therapeutics (JNCE) to Present Data from Ongoing ICONIC Trial of JTX-2011 at ASCO (streetinsider.com)
- Jounce Therapeutics (JNCE) Given a $19.00 Price Target at HC Wainwright (americanbankingnews.com)
- Wells Fargo Downgrades Jounce Therapeutics (JNCE) to Market Perform (americanbankingnews.com)
- Jounce Therapeutics (JNCE) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
Shares of NASDAQ:JNCE opened at $11.45 on Friday. The firm has a market capitalization of $539.22 million, a PE ratio of -20.09 and a beta of 6.41. Jounce Therapeutics has a 52 week low of $16.50 and a 52 week high of $17.33.
Several equities analysts have weighed in on the company. Wells Fargo downgraded Jounce Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $37.00 to $13.00 in a research report on Thursday. HC Wainwright set a $19.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Thursday. Zacks Investment Research raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. Finally, Robert W. Baird set a $35.00 price target on Jounce Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Jounce Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $21.80.
In other news, Director Barbara Gayle Duncan sold 2,000 shares of Jounce Therapeutics stock in a transaction on Thursday, March 15th. The stock was sold at an average price of $28.11, for a total value of $56,220.00. Following the completion of the sale, the director now owns 2,000 shares of the company’s stock, valued at $56,220. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Elizabeth Trehu sold 4,545 shares of Jounce Therapeutics stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $25.06, for a total value of $113,897.70. Following the completion of the sale, the insider now directly owns 4,545 shares of the company’s stock, valued at approximately $113,897.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,292 shares of company stock valued at $1,272,403.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.